← Eichor
Condition: Trastuzumab Deruxtecan Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Trastuzumab Deruxtecan

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer
Phase 2 · 1 location(s) · Yonsei University · NCT06837792Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-posit
Phase N/A · 36 location(s) · Daiichi Sankyo · NCT06846996RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07065435Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea
Phase N/A · 1 location(s) · Seoul National University Hospital · NCT06928818Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer
Phase 1 · 1 location(s) · Fudan University · NCT06331169Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer:
Phase N/A · 1 location(s) · Fundación Pública Andaluza para la Investigación Biomédica A · NCT07582887Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors,
Phase N/A · 1 location(s) · Hunan Cancer Hospital · NCT07073755Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management
Phase 2 · 27 location(s) · SOLTI Breast Cancer Research Group · NCT07371585Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
Phase N/A · 26 location(s) · Sun Yat-sen University · NCT06551220Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Trastuzumab Deruxtecan
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07537673Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or
Phase 3 · 88 location(s) · Daiichi Sankyo · NCT05950945Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic H
Phase 1 · 91 location(s) · AstraZeneca · NCT04686305Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
Phase 1 · 3 location(s) · Fox Chase Cancer Center · NCT05274048Trastuzumab Deruxtecan in Advanced Breast Cancer
Phase N/A · 1 location(s) · Wenjin Yin · NCT07180264Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease
Phase 2 · 1 location(s) · Gruppo Oncologico del Nord-Ovest · NCT06253650A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer
Phase 2 · 10 location(s) · Memorial Sloan Kettering Cancer Center · NCT07428044Trial of Trastuzumab Deruxtecan in Previously Treated HER2
Phase 2 · 3 location(s) · Yale University · NCT06750484Toxicity Markers to Trastuzumab-Deruxtecan (T-DXd) In Patients With Advanced Breast Cancer
Phase N/A · 1 location(s) · European Institute of Oncology · NCT07049133Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Chang
Phase 1 · 18 location(s) · National Cancer Institute (NCI) · NCT05372614A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
Phase 1 · 31 location(s) · Daiichi Sankyo · NCT07015697A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients
NA · 1 location(s) · Blokhin's Russian Cancer Research Center · NCT07281001Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Recep
Phase 2 · 9 location(s) · Jonsson Comprehensive Cancer Center · NCT04553770A Multi-center Real-world Efficacy and Safety of Trastuzumab-deruxtecan in Advanced Gastric Cancer
Phase N/A · 1 location(s) · Yonsei University · NCT06767436Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
Phase 2 · 1 location(s) · Shanghai Jiao Tong University School of Medicine · NCT07393425An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastas
Phase 4 · 1 location(s) · City of Hope Medical Center · NCT05376878Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients Wi
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06364410Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced
Phase 4 · 11 location(s) · Institut Claudius Regaud · NCT07195344A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
Phase N/A · 54 location(s) · Daiichi Sankyo · NCT06210776Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Phase 3 · 75 location(s) · Daiichi Sankyo · NCT07022483A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Pati
Phase 3 · 1 location(s) · Prof. Wolfgang Janni · NCT06643585
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.